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Strengths and limitations of this study
 ► The review was conducted in conformance with a 
detailed a priori published protocol, which included, 
for example, laser dose subgroup criteria.
 ► No language restrictions were applied; four (18%) 
of the included trials were reported in non-English 
language.
 ► A series of meta-analyses were conducted to esti-
mate the effect of low-level laser therapy on pain 
over time.
 ► Three persons each independently extracted the 
outcome data from the included trial articles to en-
sure high reproducibility of the meta-analyses.
 ► The review lacks quality-of-life analyses, a detailed 
disability time-effect analysis and direct compar-
isons between low-level laser therapy and other 
interventions.
AbStrACt
Objectives Low-level laser therapy (LLLT) is not 
recommended in major knee osteoarthritis (KOA) treatment 
guidelines. We investigated whether a LLLT dose–response 
relationship exists in KOA.
Design Systematic review and meta-analysis.
Data sources Eligible articles were identified through 
PubMed, Embase, Cumulative Index to Nursing and Allied 
Health Literature, Physiotherapy Evidence Database 
and Cochrane Central Register of Controlled Trials on 
18 February 2019, reference lists, a book, citations and 
experts in the field.
Eligibility criteria for selecting studies We solely 
included randomised placebo-controlled trials involving 
participants with KOA according to the American College of 
Rheumatology and/or Kellgren/Lawrence criteria, in which 
LLLT was applied to participants’ knee(s). There were no 
language restrictions.
Data extraction and synthesis The included trials were 
synthesised with random effects meta-analyses and 
subgrouped by dose using the World Association for Laser 
Therapy treatment recommendations. Cochrane’s risk-of-
bias tool was used.
results 22 trials (n=1063) were meta-analysed. Risk 
of bias was insignificant. Overall, pain was significantly 
reduced by LLLT compared with placebo at the end of 
therapy (14.23 mm Visual Analogue Scale (VAS; 95% CI 
7.31 to 21.14)) and during follow-ups 1–12 weeks later 
(15.92 mm VAS (95% CI 6.47 to 25.37)). The subgroup 
analysis revealed that pain was significantly reduced by 
the recommended LLLT doses compared with placebo at 
the end of therapy (18.71 mm (95% CI 9.42 to 27.99)) 
and during follow-ups 2–12 weeks after the end of 
therapy (23.23 mm VAS (95% CI 10.60 to 35.86)). The 
pain reduction from the recommended LLLT doses 
peaked during follow-ups 2–4 weeks after the end of 
therapy (31.87 mm VAS significantly beyond placebo 
(95% CI 18.18 to 45.56)). Disability was also statistically 
significantly reduced by LLLT. No adverse events were 
reported.
Conclusion LLLT reduces pain and disability in KOA at 
4–8 J with 785–860 nm wavelength and at 1–3 J with 
904 nm wavelength per treatment spot.
PrOSPErO registration number CRD42016035587.
IntrODuCtIOn
Approximately 13% of women and 10% of 
men in the population aged ≥60 years suffer 
from knee osteoarthritis (KOA) in the USA.1 
KOA is a degenerative inflammatory disease 
affecting the entire joint and is characterised 
by progressive loss of cartilage and associated 
with pain, disability and reduced quality of 
life (QoL).1 Increased inflammatory activity 
is associated with higher pain intensity and 
more rapid KOA disease progression.1 2
Some of the conservative intervention 
options for KOA are exercise therapy, 
non-steroidal anti-inflammatory drugs 
(NSAIDs) and anti-inflammatory low-level 
laser therapy (LLLT). There is evidence that 
exercise therapy reduces pain and disability 
and improves QoL in persons with KOA.3 4 
NSAIDs are recommended in most KOA clin-
ical treatment guidelines and is probably the 
most frequently prescribed therapy category 
for osteoarthritis, despite intake of these 
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drugs is associated with negative side effects,5 which is 
problematic, especially since the disease requires long-
term treatment. Furthermore, a recently published 
network meta-analysis indicates that the pain relieving 
effect of NSAIDs in KOA beyond placebo is small to 
moderate (depending on drug type).6 Likewise, in the 
first systematic review on this topic, the pain relieving 
effect of NSAIDs was estimated to be only 10.1 mm on 
the 0–100 mm Visual Analogue Scale (VAS) better than 
placebo.7
LLLT is a non-invasive treatment modality,8 9 which has 
been reported to induce anti-inflammatory effects.9–14 
LLLT was compared with NSAID in rats with KOA by 
Tomazoni et al in a laboratory; NSAID (10 mg diclofenac/
knee/session) and LLLT (830 nm wavelength, 6 J/knee/
session) reduced similar levels of inflammatory cells and 
metalloproteinase (MP-3 and MP-13). In addition, LLLT 
reduced the expression of proinflammatory cytokines 
(interleukin-1β (IL-1β) and IL-6 and tumour necrosis 
factor α), myeloperoxidase and prostaglandin E2 signifi-
cantly more than NSAID did.10 11
LLLT has been applied to rabbits with KOA three times 
per week for 8 weeks in a placebo-controlled experi-
ment by Wang et al.12 At the end of treatment week 6, 
they found that LLLT had significantly reduced pain and 
synovitis and the production of IL-1β, inducible nitric 
oxide synthase and MP-3 and slowed down loss of metal-
lopeptidase inhibitor 1. Two weeks later, LLLT had signifi-
cantly reduced MP-1 and MP-13 and slowed down loss of 
collagen II, aggrecan and transforming growth factor 
beta, and the previous changes were sustained.12 These 
findings indicate that the effects of LLLT increase over 
time.
Pallotta et al14 conducted a study on LLLT in rats with 
acute knee inflammation, which demonstrated that even 
though LLLT (810 nm) significantly enhanced cycloox-
ygenase (COX-1 and COX-2) expression it significantly 
reduced several other inflammatory makers, that is, 
leucocyte infiltration, myeloperoxidase, IL-1 and IL-6 and 
especially prostaglandin E2. Pallotta et al
14 hypothesised 
that the increase in COX levels by LLLT was involved in 
a production of inflammatory mediators related to the 
resolution of the inflammatory process.
LLLT is not recommended in major osteoarthritis 
treatment guidelines. LLLT for KOA was mentioned in 
the European League Against Rheumatism osteoarthritis 
guidelines (2018) but not recommended,15 and in the 
Osteoarthritis Research Society International guidelines 
(2018), it was stressed that LLLT should not be consid-
ered a core intervention in the management of KOA.16
This may be partly due to conflicting results of two 
recently published systematic reviews on the current 
topic.8 17 The conflicting results may arise from omis-
sion of relevant trials8 17–23 and unresolved LLLT dose-re-
lated issues. Only Huang et al17 conducted a LLLT 
dose–response relationship investigation in KOA, that 
is, by subgrouping the trials by laser dose, but they did 
not consider that World Association for Laser Therapy 
(WALT) recommends applying four times the laser dose 
with continuous irradiation compared to superpulsed 
irradiation.22 24–26 Thus, it was unknown whether LLLT is 
effective in KOA, and we saw a need for a new systematic 
review.
The objectives of the current review were to estimate 
the effectiveness of LLLT in KOA regarding knee pain, 
disability and QoL, and we only considered placebo-con-
trolled randomised clinical trials (RCTs) for inclusion to 
minimise risk of bias.
MEthODS
This review is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses statement 2009.27
Literature search and selection of studies
Any identified study was included if it was a placebo-con-
trolled RCT involving participants with KOA according 
to the American College of Rheumatology tool and/or 
a radiographic inspection with the Kellgren/Lawrence 
(K/L) criteria, in which LLLT was applied to participants’ 
knee(s) and self-reported pain, disability and/or QoL was 
reported. There were no language restrictions.
We updated a search for eligible articles indexed in 
PubMed, Embase, Cumulative Index to Nursing and 
Allied Health Literature, Physiotherapy Evidence Data-
base and Cochrane Central Register of Controlled 
Trials on 18 February 2019. The database search strings 
contained synonyms for LLLT and KOA, and keywords 
were added when optional. The PubMed search string 
is available in the online supplementary material. The 
search was continued by reading reference lists of all the 
eligible trial and relevant review articles,8 17 28 citations29–33 
and a laser book34 and involving experts in the field.
Two reviewers (MBS and JMB) each independently 
selected the trial articles. Both reviewers scrutinised the 
titles/abstracts of all the publications identified in the 
search, and any accessible full-text article was retrieved if it 
was judged potential eligible by at least one reviewer. Both 
reviewers evaluated the full texts of all potentially eligible 
retrieved articles and made an independent decision to 
include or exclude each article, with close attention to the 
inclusion criteria. When selection disagreements could 
not be resolved by discussion, a third reviewer (IFN) 
made the final consensus-based decision. Any retrieved 
article not fulfilling the inclusion criteria was omitted and 
listed with reason for exclusion.
risk-of-bias analysis
Two reviewers (MBS and JJ) each independently eval-
uated all included trials for risk of bias at the outcome 
level, using the Cochrane Collaboration’s risk-of-bias 
tool.35 When risk-of-bias disagreements could not be 
resolved by discussion, a third reviewer (IFN) made the 
final consensus-based decision. Likelihood of publication 
bias was assessed with graphical funnel plots.35
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Figure 1 Flow chart illustrating the trial identification 
process. CENTRAL, Cochrane Central Register of Controlled 
Trials; CINAHL, Cumulative Index to Nursing and Allied 
Health Literature; LLLT, low-level laser therapy; PEDro, 
Physiotherapy Evidence Database.
Data extraction and meta-analysis
Three reviewers (MBS, JMB and KVF) each inde-
pendently extracted the data for meta-analysis. Two of the 
reviewers (MBS and KVF) each independently collected 
the other trial characteristics. The data-extraction forms 
were subsequently compared, and data disagreements 
were resolved by consensus-based discussions. Summary 
data were extracted, unless published individual partici-
pant data were available.21 The results from the included 
trials for statistical analysis were selected from outcome 
scales in adherence to hierarchies published by Juhl et 
al.36
Pain intensity was the primary outcome. As pain 
reported with continuous, numeric and categorical/
Likert scales highly correlates with pain measured using 
the VAS, the scores of all pain scales were transformed to 
0%–100%, corresponding to 0–100 mm VAS.37 The pain 
results were combined with the mean difference (MD) 
method, primarily using change scores, that is, when 
only final scores could be obtained from a trial, change 
and final scores were mixed in the analysis, since the MD 
method allows for this without introducing bias.35
Self-reported disability results were synthesised with 
the standardised mean difference (SMD) method using 
change scores solely. The SMD was adjusted to Hedges’ 
g and interpreted as follows: SMDs of 0.2, ~0.5 and >0.8 
represent a small, moderate and large effect, respectively.35
Lack of QoL data prohibited an analysis of this outcome.
Random effects meta-analyses were conducted, and 
impact from heterogeneity (inconsistency) on the anal-
yses was examined using I2 statistics. An I2 value of 0% 
indicates no inconsistency, and an I2 value of 100% indi-
cates maximal inconsistency35; the values were catego-
rised as low (25%), moderate (50%) and high (75%).38
SDs for analysis were extracted or estimated from other 
variance data in a prespecified prioritised order: (1) SD, 
(2) SE, (3) 95% CI, (4) p value, (5) IQR, (6) median 
of correlations, (7) visually from graph or (8) other 
methods.35
The trials were subgrouped by adherence and non-ad-
herence to the WALT recommendations for laser dose 
per treatment spot, as prespecified. WALT recommends 
irradiating the knee joint line/synovia with the following 
doses per treatment spot: ≥4 J using 5–500 mW mean 
power 780–860 nm wavelength laser and/or ≥1 J using 
5–500 mW mean power (>1000 mW peak power) 904 nm 
wavelength laser.24 25
The main meta-analyses were conducted using two 
prespecified time points of assessment, that is, immedi-
ately after the end of LLLT and last time point of assess-
ment 1–12 weeks after the end of LLLT (follow-up).
MBS performed the meta-analyses, under supervi-
sion of JMB, using the software programme Excel 2016 
(Microsoft) and Review Manager Version V.5.3 (Copen-
hagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014).
Patient and public involvement
Patients or the public were not involved in the conceptu-
alisation or carrying out of this research.
rESuLtS
In total, 2735 records were identified in the search, of 
which 22 trial articles were judged eligible and included 
in the review (n=1089; figure 1 and tables 1–2) with data 
for meta-analysis (n=1063). Four included trials were 
not reported in the English language19 21 23 39 and one 
included trial was unpublished (Gur and Oktayoglu). 
Excluded articles initially judged potentially eligible were 
listed with reasons for omission (online supplementary 
material).
At the group level, the mean age of the participants was 
60.25 (50.11–69) years (data from 19 trials), the mean 
percentage of women was 69.63% (0–100%; data from 17 
trials), the mean body mass index of the participants was 
29.55 (25.8–38; data from 14 trials), the mean of median 
K/L grades was 2.37 (data from 13 trials) and the mean 
baseline pain was 63.61 mm VAS (35.25–92) (data from 22 
trials). LLLT was used as an adjunct to exercise therapy in 
11 trials. The mean duration of the treatment periods was 
3.53 weeks with the recommended LLLT doses and 3.7 
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Table 1 Characteristics of the included trials
First author
Intervention group at 
baseline
Control group at 
baseline
Intervention versus control 
programme
Outcome scales, week of 
reassessment










VAS pain: 59 mm
K/L: -
3 weeks of exercise therapy, advice 
and LLLT versus 3 weeks of exercise 




Week of assessment: 2, 3, 9, 
29










VAS pain: 35.4 mm
K/L: 2
3 weeks of LLLT followed by 8 weeks 
of exercise therapy versus 3 weeks 





Week of assessment: 3, 11, 
24, 37










VAS pain: 75.5 mm
K/L: 2
4 weeks of exercise therapy, heat 
packs and LLLT versus 4 weeks of 





Week of assessment: 4










VAS pain: 59 mm
K/L: –
2 weeks of exercise therapy, 
therapeutic ultrasound, TENS and 
LLLT versus 2 weeks of exercise 
therapy, therapeutic ultrasound, 
TENS and sham LLLT
Pain: WOMAC (VAS) 0–100
Disability: WOMAC
QoL: –
Week of assessment: 2










VAS pain: 56.35 mm
K/L: –
3 weeks of LLLT versus 3 weeks of 
sham LLLT




Week of assessment: 3, 6










VAS pain: 45 mm
K/L: –
2 weeks of exercise therapy, 
therapeutic ultrasound, TENS and 
LLLT versus 2 weeks of exercise 
therapy, therapeutic ultrasound, 




Week of assessment: 2, 8










VAS pain: 62 mm
K/L: 2





Week of assessment: 3










VAS pain: 67.4 mm
K/L: 2
14 weeks of exercise therapy and 
2 weeks of LLLT versus 14 weeks 





Week of assessment: 6, 10, 14










VAS pain: 67.4 mm
K/L: 2
14 weeks of exercise therapy and 
2 weeks of LLLT versus 14 weeks 





Week of assessment: 6, 10, 14










VAS pain: 92 mm
K/L: 3
14 weeks of exercise therapy and 
2 weeks of LLLT versus 14 weeks 
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First author
Intervention group at 
baseline
Control group at 
baseline
Intervention versus control 
programme
Outcome scales, week of 
reassessment

















Week of assessment: 2










VAS pain: 56.2 mm
K/L: 2





Week of assessment: 4, 6, 12










VAS pain: 54.1 mm
K/L: 3





Week of assessment: 2, 5, 7










VAS pain: 43 mm
K/L: –





Week of assessment: 12, 52










VAS pain: 72.6 mm
K/L: –





Week of assessment: 1










VAS pain: 78.7 mm
K/L: 2.5
6 weeks of exercise therapy and LLLT 





Week of assessment: 6










VAS pain: 65.5 mm
K/L: 3
2 weeks of exercise therapy and LLLT 





Week of assessment: 2, 4










VAS pain: 80 mm
K/L: 2





Week of assessment: 4










VAS pain: 76 mm
K/L: 3.2
4 weeks of exercise therapy, kinesio 
tape and LLLT versus 4 weeks of 





Week of assessment: 4, 8










VAS pain: 58 mm
K/L: –
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First author
Intervention group at 
baseline
Control group at 
baseline
Intervention versus control 
programme
Outcome scales, week of 
reassessment










VAS pain: 52 mm
K/L:<4





Week of assessment: 6, 14










VAS pain: 63.88 mm
K/L: 2





Week of assessment: 3, 26










VAS pain: 63.88 mm
K/L: 2





Week of assessment: 3, 26












VAS pain: 50 mm
K/L: 2
8 weeks of exercise therapy and LLLT 





Week of assessment: 8












VAS pain: 50 mm
K/L: 2
8 weeks of exercise therapy and LLLT 





Week of assessment: 8
The values for age and body mass index (BMI) are means and the values for K/L grade are medians. Baseline Visual Analogue Scale (VAS) scores 
have been extracted or estimated as described in the Method section. Week of assessment in bold denotes time point used for the main meta-
analyses.
AQoL-6D, Assessment of Quality of Life 6 Dimensions; DIQ, Disability Index Questionnaire; K/L, Kellgren/Lawrence; LLLT, low-level laser therapy; 
NRS, Numeric Rating Scale; QoL, quality of life; SKFS, Saudi Knee Function Scale; TENS, Transcutaneous Electrical Nerve Stimulation; VNPS, Visual 
Numerical Pain Scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 1 Continued
weeks with the non-recommended LLLT doses (tables 1 
and 2). Non-recommended LLLT doses were applied in 
nine of the trials. That is, Al Rashoud et al,31 Bülow et al,20 
Tascioglu et al40 and Bagheri et al23 applied too few (<4) 
Joules per treatment spot with 830 nm wavelength, Jensen 
et al,21 Nivbrant et al19 and Hinman et al41 applied too few 
(<1) Joules per treatment spot with 904 nm wavelength 
and Youssef et al42 (one group) and Rayegani et al43 used 
continuous laser with too long of a wavelength (880 nm; 
table 2). No adverse event was reported by any of the 
trial authors. None of the trial authors stated receiving 
funding from the laser industry (online supplementary 
material).
Overall, pain was significantly reduced by LLLT 
compared with the placebo control at the end of therapy 
(14.23 mm VAS (95% CI 7.31 to 21.14); I2=93%; n=816; 
figure 2) and during follow-ups 1–12 weeks later (15.92 
mm VAS (95% CI 6.47 to 25.37); I2=93%; n=581; figure 3). 
The dose subgroup analyses demonstrated that pain was 
significantly reduced by the recommended LLLT doses 
compared with placebo at the end of therapy (18.71 mm 
(95% CI 9.42 to 27.99); I2=95%; n=480; figure 2) and 
during follow-ups 2–12 weeks later (23.23 mm VAS (95% 
CI 10.60 to 35.86); I2=95%; n=392; figure 3). The dose 
subgroup analyses demonstrated that pain was signifi-
cantly reduced by the non-recommended LLLT doses 
compared with placebo at the end of therapy (6.34 mm 
VAS (95% CI 1.26 to 11.41); I2=44%; n=336; figure 2), 
but the difference during follow-ups 1–12 weeks later was 
not significant (6.20 mm VAS (95% CI −0.65 to 13.05); 
I2=38%; n=189; figure 3). The between-subgroup differ-
ences (recommended versus non-recommended doses) 
in pain results were significantly in favour of the recom-
mended LLLT doses regarding both time points (p=0.02 
and 0.02; figures 2 and 3).
Overall, disability was significantly reduced by LLLT 
compared with placebo at the end of therapy (SMD=0.59 
(95% CI 0.33 to 0.86); I2=57%; n=617; figure 4) and during 
follow-ups 1–12 weeks later (SMD=0.66 (95% CI 0.23 to 
1.09); I2=67%; n=289; figure 5). The dose subgroup anal-
yses demonstrated that disability was significantly reduced 
by the recommended LLLT doses compared with placebo 
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Table 2 Laser therapy characteristics of the included trials















Al Rashoud 201431* Knee joint line (medial and lateral) 
and acupoints (SP9, SP10, ST36)
830 1.2 30 40 5 9/3
Alfredo 2011, 201829 52 Knee joint line (medial and lateral) 904 3 60 50 9 9/3
Alghadir 201432 Knee condyles, joint line (medial 
and lateral) and popliteal fossa
850 6 100 60 8 8/2
Bagheri 201123* Knee joint line 830 3 30 100 10 10/5
Bülow 199420* Painful spots in 0–10 cm radius of 
the knee joint line
830 1.5–4.5 25 60–180 5–15 9/3
Delkhosh 201839 Knee joint 830 5 30 167 5 10/5
Fukuda 201130 Front knee capsule 904 3 60 50 9 9/3
Gur 200333 (1.5 J) Anterolateral and anteromedial 
portal of the knee
904 1.5 10 150 2 10/5
Gur 200333 (1 J) Anterolateral and anteromedial 
portal of the knee
904 1 11.2 90 2 10/5
Gur and Oktayoglu Anterolateral and anteromedial 
portal of the knee
904 1.5 10 150 2 10/5
Gworys 201218 Knee joint line, patellofemoral joint 
and popliteal fossa
810 8 400 20 12 10/5
Hegedűs 200953 Knee joint line, popliteal fossa and 
condyles
830 6 50 120 8 8/2
Helianthi 201654 Knee joint line (lateral) and 
acupoints (ST36, SP9, GB34, EX-
LE-4)
785 4 50 80 5 10/2
Hinman 201441* Acupoints (locations not stated) 904 0.2 10 20 6 8-12/0.67–1
Jensen 198721* Knee joint line (medial and lateral), 
apex and basis of patellae
904 0.054 0.3 180 4 5/5
Kheshie 201447† Front knee 830 – 160 – – 12/2
Koutenaei 201755 Front knee, popliteal fossa and 
femur condyles in the popliteal 
cavity
810 7 100 70 8 10/5
Mohammed 201856 Knee joint line (lateral) and 
acupoints (ST36, Sp10, GB, ashi)
808 5.4 90 60 7 12/3
Nambi 201648 Knee joint line, condyles and 
popliteal fossa
904 1.5 25 60 8 12/3
Nivbrant 199219* Knee joint line (medial and lateral) 
and acupoints (ST34, SP10, X32)
904 0.72 4 180 7 6/3
Rayegani 201243* Knee joint line and popliteal fossa 880 6 50 120 8 10/5
Tascioglu 200440 (3 J)* Painful spots on the knee 830 3 50 60 5 10/5
Tascioglu 200440 (1.5 
J)*
Painful spots on the knee 830 1.5 50 30 5 10/5
Youssef 201642 (904 
nm)
Knee joint line (medial and lateral) 904 3 60 50 9 16/2
Youssef 201642 (880 
nm)*
Knee joint line (medial and lateral), 
epicondyles and popliteal fossa
880 6 50 120 8 16/2
*Non-recommended low-level laser therapy dose.
†1250 Joules per session.
at the end of therapy (SMD=0.75 (95% CI 0.46 to 1.03); 
I2=34%; n=339; figure 4) and during follow-ups 2–8 weeks 
later (SMD=1.31 (95% CI 0.92 to 1.69); I2=0%; n=129; 
figure 5). The dose subgroup analyses demonstrated 
that disability was neither significantly reduced by the 
non-recommended LLLT doses compared with placebo 
at the end of therapy (SMD=0.36 (95% CI −0.02 to 0.73); 
I2=49%; n=278; figure 4) nor during follow-ups 1–12 
weeks later (SMD=0.26 (95% CI −0.06 to 0.58); I2=0%; 
n=160; figure 5). The between-subgroup differences in 
disability results were in favour of the recommended 
LLLT doses over the non-recommended LLLT doses 
but only significantly regarding one of two time points 
(p=0.11 and <0.0001; figures 4–5).
No QoL meta-analysis was performed because this 
outcome was only assessed in a single trial, that is, by 
Hinman et al who applied a non-recommended LLLT 
dose and reported insignificant results.41
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Figure 2 Pain results from immediately after the end of therapy. LLLT, low-level laser therapy.
Figure 3 Pain results from follow-ups 1–12 weeks after the end of therapy. LLLT, low-level laser therapy.
The funnel plots indicated that there was no publica-
tion bias (online supplementary material). We addition-
ally checked for small study bias by reducing the statistical 
weight of the smallest studies through a change from 
random to fixed effects models and this led to similar 
mean effect estimates, indicating that there was no small 
study bias (online supplementary material).35
Methodological quality of the included trials was 
judged adequate (low risk of bias), unclear (unclear risk 
of bias) and inadequate (high risk of bias) in 75%, 19% 
and 6% instances, respectively. Risk of detection bias 
and reporting bias appeared low in all the trials. There 
was a lack of information regarding random sequence 
generation in five trials, allocation concealment in 12 
trials, blinding of therapist in four trials and incom-
plete outcome data in four trials. Therapist blinding was 
inadequate in seven trials and there was an inadequate 
handling of data in a single trial (figure 6). However, 
risk-of-bias subgroup analyses conducted post hoc 
revealed that there was no statistically significant inter-
action between the effect estimates and risk of bias, and 
the analyses did not display a drop in statistical heteroge-
neity (online supplementary material). Support for our 
risk of bias judgments is available (online supplementary 
material).
Neither did the levels of statistical heterogeneity change 
when we switched from the MD to the SMD method post 
hoc (online supplementary material).
Post hoc analyses demonstrated that LLLT was signifi-
cantly superior to placebo both with exercise therapy 
(p=0.0009 for pain and p<0.0001 for disability) and 
without exercise therapy (p=0.01 for pain and p=0.008 
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Figure 4 Disability results from immediately after the end of therapy. LLLT, low-level laser therapy.
Figure 5 Disability results from follow-ups 1–12 weeks after the end of therapy. LLLT, low-level laser therapy.
for disability) as cointervention (online supplementary 
material).
Post hoc analyses were performed to more precisely esti-
mate the pain time-effect profile for the recommended 
LLLT doses by imputing the results of the trials with these 
doses in subgroups with narrower time intervals. Pain was 
significantly reduced by the recommended LLLT doses 
compared with placebo immediately after therapy weeks 
2–3 and 4–8 and at follow-ups 2–4, 6–8 and 12 weeks later; 
the peak point was 2–4 weeks after the end of therapy 
(31.87 mm VAS beyond placebo (95% CI 18.18 to 45.56); 
I2=93%; n=322). The 21-week and 34-week follow-up 
pain results were not statistically significant (figure 7 and 
online supplementary material). The statistical hetero-
geneity in the main pain analyses of the recommended 
LLLT doses was high (I2=95%; figures 2–3) but the mean 
statistical heterogeneity of the five subgroups covering the 
same time period was only moderate (I2=58%; figure 7 
and online supplementary material).
DISCuSSIOn
Our meta-analyses showed that pain and disability were 
significantly reduced by LLLT compared with placebo. 
We subgrouped the included trials according to the 
WALT recommendations (2010) for laser dose per treat-
ment spot, and this revealed a significant dose–response 
relationship. Our principal finding is that the recom-
mended LLLT doses offer clinically relevant pain relief in 
KOA. The non-recommended LLLT doses provided no 
or little positive effect.
The absolute minimally clinically important improve-
ment (MCII) of pain in KOA has been estimated to be 
19.9, 17 and 9 units on a 0–100 scale in 2005, 2012 and 
2015, respectively.44–46 It is important to note that the MCII 
of pain is a within-subject improvement and depends on 
baseline pain intensity.44–46 The pain reduction from the 
recommended LLLT doses was significantly superior 
to placebo even at follow-ups 12 weeks after the end of 
therapy, and the difference was greater than 20 mm VAS 
from the final 4–8 weeks of therapy through follow-ups 
6–8 weeks after the end of therapy. Interestingly, the pain 
reduction from the recommended LLLT doses peaked at 
follow-ups 2–4 weeks after the end of therapy (31.87 mm 
VAS highly significantly beyond placebo).
Disability was also significantly reduced by the recom-
mended LLLT doses compared with placebo, that is, to 
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Figure 6 Risk-of-bias plot of the included trials. The trials 
are ranked by mean pain effect estimates, that is, more laser 
positive results in the bottom of the figure; the plot is based 
on the results from the main pain analyses (immediately after 
the end of therapy, primarily).
a moderate extent at the end of therapy (SMD=0.75) 
and to a large extent during follow-ups 2–8 weeks later 
(SMD=1.31). More trials with disability assessments are 
needed to precisely estimate the effect of LLLT on this 
outcome during follow-up.
Furthermore, our analyses demonstrated that LLLT is 
effective in KOA both with and without exercise therapy 
as cointervention. Strength training was seemingly 
only used as an adjunct to LLLT in two of the included 
trials,47 48 and thus more trials with this combination of 
treatments are needed.
Risk of bias of the included trials appeared insignifi-
cant and could not explain the statistical heterogeneity 
(online supplementary material). We find it plausible that 
some of the statistical heterogeneity of the overall anal-
yses is associated with the dose subgroup criteria (wave-
length-specific laser doses per treatment spot) since the 
mean levels of statistical heterogeneity of the subgroup 
analyses were consistently lower than the overall levels. It 
is unknown to us whether other differences in the LLLT 
protocols impacted the results.
The statistical heterogeneity in the main pain analyses 
of the recommended LLLT doses was high, and some of 
it can be explained by the pooling of results from various 
time points of assessment given the pain reduction 
increased and subsequent decreased with time; the pain 
reduction time profile showed a drop in statistical hetero-
geneity to a moderate level.
According to WALT, the osteoarthritic knee should be 
laser irradiated to reduce inflammation and promote 
tissue repair.24 25 49 One of the discrepancies from our 
review and previously published reviews of the same topic 
is that we omitted the RCT by Yurtkuran et al,8 17 28 50 as 
they solely applied laser to an acupoint located distally 
from the knee joint (spleen 9).
In line with our findings and the WALT dose recom-
mendations, Joensen et al26 observed that the percentage 
of laser penetrating rat skin at 810 and 904 nm wave-
length was 20% and 38%–58%, respectively. That is, to 
deliver the same dose beneath the skin, 2.4 times the 
energy on the skin surface is required with an 810 nm 
laser compared with a 904 nm laser device. This may be 
due to the different wavelengths and/or because 904 
nm laser is superpulsed (pulse peak power ≥10 000 mW 
typically), whereas shorter wavelength laser is delivered 
continuously or with less intense pulsation.26 The esti-
mated median dose applied with the recommended 
LLLT was 6 and 3 J per treatment spot with 785–860 and 
904 nm wavelength laser, respectively. Most of the trial 
authors reported LLLT parameters in detail but did not 
state whether the laser devices were calibrated. There-
fore, in the LLLT trials with non-significant effect esti-
mates, equipment failure cannot be ruled out.
It is important to note that no adverse events were 
reported by any of the trial authors and the dropout rate 
was minor, indicating that LLLT is harmless.
Our clinical findings that the effect of LLLT progresses 
over time is in line with in vivo results of Wang et al.12 The 
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Figure 7 Pain time-effect profile (recommended low-level laser therapy (LLLT) doses versus placebo-control). Values on the 
y-axis are mm Visual Analogue Scale (VAS) pain results. Positive VAS score indicates that the recommended LLLT doses are 
superior to placebo. The related forest plot is available (online supplementary material). **The recommended LLLT doses are 
highly statistically significantly superior to placebo (p≤0.01).
positive effect from LLLT seems to last longer than those 
of widely recommended painkiller drugs.51 The effect of 
using the NSAID tiaprofenic acid, for example, is probably 
gone within a week, unless the treatment is continued.51 
Future trials should investigate whether booster sessions 
of LLLT can prolong the positive effect. Comparative 
cost-effectiveness analyses of LLLT and NSAIDs would 
also be of great interest.
Strengths and limitations of this study
In contrast to previous reviews on the current topic, our 
review was conducted in conformance with an a priori 
published protocol,8 17 28 which included a detailed plan 
for statistical analysis (eg, laser dose subgroup criteria). 
Furthermore, this is the first review on this topic without 
language restrictions,8 17 28 and this expansion proved 
important since four (18%) of the included trials were 
reported in non-English language.19 21 23 39
We conducted a series of meta-analyses illustrating the 
effect of LLLT on pain over time. To ensure high repro-
ducibility of the meta-analyses, three persons each inde-
pendently extracted the outcome data from the included 
trial articles.
This review is not without limitations. It lacks QoL anal-
yses, a detailed disability time-effect analysis and direct 
comparisons between LLLT and other interventions.
COnCLuSIOnS
LLLT reduces pain and disability in KOA at 4–8 J with 
785–860 nm wavelength and at 1–3 J with 904 nm wave-
length per treatment spot.
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